Invitae appoints David Sholehvar as COO

Invitae appointed David Sholehvar as Chief Operating Officer, effective November 13. Sholehvar most recently held the role of president, clinical services division, at NeoGenomics, an oncology diagnostics company, where he was responsible for the commercial and strategic growth of the clinical services division. From 2017 to 2020, Sholehvar served as CEO for Dynex Technologies, a manufacturer of laboratory instruments and associated consumables and accessories. Prior to Dynex, Sholehvar spent four years with Quest Diagnostics, serving as vice president of Quest’s largest sales region from 2014 to 2017, and general manager of infectious disease and immunology from 2013 to 2014. Sholehvar has also served as VP for the Americas and EMEA for Ortho Clinical Diagnostics, a former Johnson & Johnson company, and general manager for Cellular Technologies, a former Johnson & Johnson company. Pursuant to his hiring as Invitae’s COO, Invitae is granting 850,000 restricted stock units to Sholehvar under Invitae’s 2015 Stock Incentive Plan, which will be amended and restated to add 850,000 shares of Invitae common stock to a pool of shares under the 2015 Plan. One-third of the RSUs will vest on each of the first three anniversaries of November 15, 2023, subject to Sholehvar’s continued service as an employee of Invitae through the applicable vesting dates.